A Study of RAY1225 in Participants With Obesity
ConditionObesity
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorGuangdong Raynovent Biotech Co., Ltd
About this trial
The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with Obesity. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.
Eligibility criteria
Qualifiers
Have a body mass index (BMI) of ≥28 kilogram per square meter (kg/m²) or ≥24 kg/m² and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, fatty liver disease,or HbA1c ≥5.7% and < 6.5%;
Participants (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product.
Disqualifiers
Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
with a history of diabetes or hypoglycemia;
Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2 or with thyroid nodules of unknown etiology found at screening and considered clinically significant by the investigator.
Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed >1 year prior to screening)
Trial design
Treatments tested in this trial
- RAY1225
- Placebo
Treatment groups
270 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov